(224 days)
NCCLS Frozen Trovafloxacin Reference Panels
Not Found
No
The device description and performance studies focus on traditional microbiological methods (microdilution, visual reading) and do not mention any AI or ML components.
No
This device determines bacterial susceptibility to an antimicrobial agent, which is a diagnostic function, not a therapeutic one. It provides information to guide treatment, but does not directly treat a condition.
Yes
The device is intended to determine bacterial susceptibility to an antimicrobial agent, which is a diagnostic purpose to inform treatment decisions.
No
The device description explicitly states "Microdilution Minimum Inhibitory Concentration (MIC) Panels" and describes a physical manufacturing process involving dehydrated substances in wells, inoculation, incubation, and visual reading. This indicates a physical, hardware-based device, not a software-only one.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is to "determine gram-negative and gram-positive bacterial susceptibility against the antimicrobial agent Trovafloxacin." This is a diagnostic test performed on biological samples (bacterial isolates) to provide information about a patient's potential response to an antibiotic.
- Device Description: The device is a "Microdilution Minimum Inhibitory Concentration (MIC) Panel." MIC panels are a standard method used in clinical microbiology laboratories to determine the lowest concentration of an antimicrobial agent that inhibits the visible growth of a microorganism. This is a diagnostic procedure.
- Performance Studies: The document describes clinical trials and performance evaluations comparing the device to a "NCCLS frozen Trovafloxacin Reference Panel." These studies are conducted to demonstrate the accuracy and reliability of the device for its intended diagnostic purpose.
- Key Metrics: The document reports "Essential Agreement," which is a metric used to evaluate the performance of antimicrobial susceptibility testing devices.
All of these points strongly indicate that the device is intended for in vitro diagnostic use. It is a test performed outside of the body on a biological sample to aid in the diagnosis and treatment of bacterial infections.
N/A
Intended Use / Indications for Use
MicroScan® Dried Gram-Negative and Gram-Positive MIC/Combo Panels with Trovafloxacin (0.03 - 8 mcg/ml on the gram-negative panels and 0.06 - 8mcg/ml on the gram-positive panels) To determine gram-negative and gram-positive bacterial susceptibility against the antimicrobial agent Trovafloxacin. Organisms with indications for testing* include: Gram-Negative Bacteria Escherichia coli Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Gram-Positive Bacteria Methicillin susceptible Staphylococcus aureus Methicillin susceptible Staphylococcus epidermidis Enterococcus faecalis Streptococcus agalactiae (Gp.B) Streptococcus pyogenes (Gp.A) * As taken from the Indications and Usage section of the manufacturer's package insert (Issued: December 1997). The MicroScan® Dried Gram-Negative and Gram-Positive MIC/Combo Panels with Trovafloxacin are not intended for use with Streptococcus pneumoniae and viridans streptococci.
Product codes (comma separated list FDA assigned to the subject device)
JWY
Device Description
The proposed MicroScan® Dried Gram-Negative and Gram-Positive MIC/Combo Panel with Trovalloxacin. The manufacturing process for both Test panels called for Trovafloxacin dehydrated in Mueller-Hinton broth. During testing each well was inoculated/rehydrated with the organisms suspended in distilled water with Pluronic * Test panels were read visually after 16-20 hours of incubation at 35° C in a non-CO2 incubator.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
The Premarket Notification (510(k)) presents data in support of the new antimicrobial. Trovafloxacin, for the MicroScan® Dried Gram Negauve and Gram Positive MIC/Combo Panels. Both the gram-negative and gram-posuive external evaluations were conducted with fresh and stock Efficacy isolates and stock Challenge strains. The external evaluations were designed to confirm the acceptability of the proposed Dried Trovafloxacin panels by comparing their performance with an NCCLS frozen Trovationacin Reference panel. The clinical trial panels also included 2 other gram-negative antibiotics and 3 other gram-positive antibiotics. Only the Trovafloxacin data are included in this Premarket Notification submission. The Clinical Trial protocol called for an Efficacy phase (stock and fresh isolates), a CDC Challenge (CDC challenge strains), and Reproducibility (inoculum and instrument). The Reproducibility isolates are provided in Section 2 .: Inoculum and Instrument Reproducibility Amendment. Throughout each phase Quality Control isolates were also tested. Performance was evaluated by comparing both proposed devices (gram-negative and gram-positive) with frozen NCCLS reference panels and clinical isolates with a broad range of susceptibilities for the 3 gram-negative antibiotics and 4 gram-positive antibiotics on the clinical trial panel. The type and number of isolates tested was in compliance with the FDA guidance "Review Criteria for Assessment of Antimicrobial Susceptibility Devices: Draft May 1991". The clinical study was conducted between June and September 1998. The MicroScan® Dried Gram-Negative and Gram-Positive Panels (Test panels) contained doubling dilutions of Trovafloxacin from 0.002 to 8 mcg/ml. Data are presented on the gram-negative panel for the 9 dilutions (i.e., 0.03 - 8 mcg/ml), and on the gram-positive panel for the 8 dilutions (i.e., 0.06 - 8 mcg/ml) for which approval is requested. Initial data analysis was performed by comparing the initial Test MIC results with the initial Reference MIC results. As indicated in the Clinical Trial protocol, isolates that exhibited a greater than or equal to 2 dilution error (discrepancy) between the Test and the Reference panel were repeated in triplicate. Final data analysis was performed by comparing the initial Test results to the repeat Reference results. Discrepancies were considered resolved when the repeat Reference result was in Essential Agreement with the initial Test result. An additional data analysis was also performed using repeat results from both the Reference and the Test panels. The Initial, Final, and Additional Data Analyses summaries are presented separately and are identified accordingly. Both Clinical Trials consisted of 3 different test phases; Efficacy, CDC Challenge, and Reproducibility. Quality Control was performed daily. Data from the Efficacy and CDC Challenge phases were evaluated using the same Error and Agreement definitions.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The Dried gram-negative Trovafloxacin panel demonstrated acceptable performance with an overall Essential Agreement of 99.7% when compared with the frozen Trovafloxacin Reference panel. The Dried gram-positive Trovatioxacin panel demonstrated acceptable performance with an overall Essential Agreement of 98.7% when compared with the frozen Trovafloxacin Reference panel. Inoculum and instrument reproducibility testing was conducted: both the gram-negative and the gram-positive Dried Trovafloxacin panels demonstrated acceptable reproducibility and precision. regardless of which inoculum method (i.e. Turbidity and Prompt), or instrument (autoScan-48 and WalkAway") was used. Quality Control performance was acceptable for both the gram-negative and the gram-positive Dried Trovafloxacin panels.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Essential Agreement of 99.7% (gram-negative); Essential Agreement of 98.7% (gram-positive).
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
NCCLS Frozen Trovafloxacin Reference Panels
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.1640 Antimicrobial susceptibility test powder.
(a)
Identification. An antimicrobial susceptibility test powder is a device that consists of an antimicrobial drug powder packaged in vials in specified amounts and intended for use in clinical laboratories for determining in vitro susceptibility of bacterial pathogens to these therapeutic agents. Test results are used to determine the antimicrobial agent of choice in the treatment of bacterial diseases.(b)
Classification. Class II (performance standards).
0
MAY 10 ----
DADE MICROSCAN INC. 1584 Enterprise Boulevard West Sacramento, CA 95691 Tel: +1 (916) 372-1900
Dade Behring
510(k) Summary
510(k) Submission Information:
| Device Manufacturer: | Dade MicroScan Inc. |
|---|---|
| Contact name: | Sharolyn Lentsch. Regulatory Affairs Manager |
| Fax: | 916-374-3144 |
| Date prepared: | September 25, 1998 |
| Product Name: | Microdilution Minimum Inhibitory Concentration (MIC) Panels |
| Trade Name: | MicroScan® Dried Gram-Negative and Gram-Positive MIC/Combo Panels |
| Intended Use: | To determine antimicrobial agent susceptibility |
| 510(k) Notification: | New antimicrobial - Trovafloxacin |
| Predicate device: | NCCLS Frozen Trovafloxacin Reference Panels |
510(k) Summarv:
The proposed MicroScan® Dried Gram-Negative and Gram-Positive MIC/Combo Panel with Trovalloxacin demonstrated substantially equivalent performance with an NCCLS frozen Trovationacin Reference Panel, as defined in the FDA DRAFT document "Review Criteria for Assessment of Antimicrobial Susceptibility Devices" (dated May 31, 1991).
The Premarket Notification (510(k)) presents data in support of the new antimicrobial. Trovafloxacin, for the MicroScan® Dried Gram Negauve and Gram Positive MIC/Combo Panels.
Both the gram-negative and gram-posuive external evaluations were conducted with fresh and stock Efficacy isolates and stock Challenge strains. The external evaluations were designed to confirm the acceptability of the proposed Dried Trovafloxacin panels by comparing their performance with an NCCLS frozen Trovafloxacin Reference panel.
The Dried gram-negative Trovafloxacin panel demonstrated acceptable performance with an overall Essential Agreement of 99.7% when compared with the frozen Trovafloxacin Reference panel. The Dried gram-positive Trovatioxacin panel demonstrated acceptable performance with an overall Essential Agreement of 98.7% when compared with the frozen Trovafloxacin Reference panel.
Inoculum and instrument reproducibility testing was conducted: both the gram-negative and the grampositive Dried Trovafloxacin panels demonstrated acceptable reproducibility and precision. regardless of which inoculum method (i.e. Turbidity and Prompt), or instrument (autoScan-48 and WalkAway") was used.
Quality Control performance was acceptable for both the gram-negative and the gram-positive Dried Trovafloxacin panels.
1
Section 1. SUMMARY OF CLINICAL STUDIES
Purpose/Scope
The purpose of the clinical studies was to demonstrate that MicroScan® Dried Gram-Negative and Gram-Positive MIC/Combo panels with Trovafloxacin (Test panels) are substantially equivalent to frozen NCCLS reference panels (Reference panels). Device performance was evaluated in a clinical trial that included gram-negative and grampositive isolates. The study is summarized in this Premarket Notification. The clinical trial panels also included 2 other gram-negative antibiotics and 3 other gram-positive antibiotics. Only the Trovafloxacin data are included in this Premarket Notification submission.
Trovafloxacin - Indications & Usage, Microbiology, and Mechanisms of Resistance
In general, Trovafloxacin is a new fluoronaphthyridone related to the fluoroquinolones. The bactericidal action of Trovafloxacin results from inhibition of DNA gyrase and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division. The mechanism of action of fluoroquinolones including Trovafloxacin is different from that of penicillins, cephalosporins, aminoglycosides, macrolides, and tetracyclines. Therefore, fluoroquinolones may be active against pathogens that are resistant to these antibiotics. Resistance to Trovafloxacin in vitro develops slowly via multiple-step mutation in a manner similar to other fluoroguinolones. Although cross-resistance has been observed between Trovatloxacin and some other fluoroquinolones, some microorganisms resistant to other fluoroquinolones may be susceptible to Trovafloxacin. 1
Trovafloxacin is indicated for treatment of pneumonia, bronchitis, acute sinusitis, various internal and skin infections, prostatitis, urethral gonorrhea, cervicitis, and pelvic inflammatory disease, when caused by susceptible strains.
Figure 1 presents the aerobic and facultatively anaerobic gram-negative and gram-positive genera listed under the Indications and Usage section for the antimicrobial Trovatloxacin (as taken from the Pfizer Trovan product insert, issued: December 1997). Also highlighted in the table are the bacteria listed under the Microbiology section of the same product insert.
Pfizer Trovan™ (Trovatloxacin) Package Insert, Issued December 1997.
2
| Gram-Negatives | |
|---|---|
| Indications and Usage Isolates | Microbiology Isolates |
| Escherichia coli | Citrobacter freundii |
| Klebsiella pneumoniae | Enterobacter aerogenes |
| Proteus mirabilis | Morganella morganii |
| Pseudomonas aeruginosa | Proteus vulgaris |
| Figure 1 | ||
|---|---|---|
| Trovafloxacin Intended Use Isolates2 |
| Gram-Positives | |
|---|---|
| Indications and Usage Isolates | Microbiology Isolates |
| Enterococcus faecalis | Streptococcus pneumoniae |
| (penicillin resistant) | |
| Staphylococcus aureus | |
| (Methicillin-susceptible) | |
| Staphylococcus epidermidis | |
| (Methicillin-susceptible) | |
| Streptococcus agalactiae (Gp B) | |
| Streptococcus pyogenes (Gp A) | |
| Streptococcus pneumoniae | |
| (penicillin susceptible) | |
| Viridans group streptococci |
Clinical Investigations
A copy of the Clinical Trial protocol is provided in Section 2.:Clinical Trial Protocol. The Clinical Trial protocol called for an Efficacy phase (stock and fresh isolates), a CDC Challenge (CDC challenge strains), and Reproducibility (inoculum and instrument). The Reproducibility isolates are provided in Section 2 .: Inoculum and Instrument Reproducibility Amendment. Throughout each phase Quality Control isolates were also tested. Performance was evaluated by comparing both proposed devices (gramnegative and gram-positive) with frozen NCCLS reference panels and clinical isolates with a broad range of susceptibilities for the 3 gram-negative antibiotics and 4 gram-positive antibiotics on the clinical trial panel. The type and number of isolates tested was in compliance with the FDA guidance "Review Criteria for Assessment of Antimicrobial Susceptibility Devices: Draft May 1991".
After completion of the gram-negative clinical trial, a decision was made to map the dilution range from 0.002 - 8 mcg/ml to 0.03 - 8 mcg/ml due to variable performance with the low end dilutions. Similarly, a decision was made to map several gram-positive dilutions due to variable performance; the 0.002 - 8 mcg/ml range was mapped up to 0.06 - 8 mcg/ml.
4 Pfizer Trovan™ (Trovafloxacin) Package Insert. Issued December 1997.
3
The clinical study was conducted between June and September 1998. A description of each clinical site and their role in the testing is presented in the clinical trial protocol, Section 2.
The MicroScan® Dried Gram-Negative and Gram-Positive Panels (Test panels) contained doubling dilutions of Trovafloxacin from 0.002 to 8 mcg/ml. Data are presented on the gram-negative panel for the 9 dilutions (i.e., 0.03 - 8 mcg/ml), and on the gram-positive panel for the 8 dilutions (i.e., 0.06 - 8 mcg/ml) for which approval is requested.
The manufacturing process for both Test panels called for Trovafloxacin dehydrated in Mueller-Hinton broth. During testing each well was inoculated/rehydrated with the organisms suspended in distilled water with Pluronic * Test panels were read visually after 16-20 hours of incubation at 35° C in a non-CO2 incubator.
Reference panels were made according to NCCLS recommendations found in NCCLS Document M7-A4 (Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, fourth edition; Approved Standard. Pennsylvania, NCCLS, 1997), using cation adjusted Mueller-Hinton broth. The Reference panels were read visually after 16-20 hours of incubation at 35° C in a non-CO2 incubator (see Section 2.: Clinical Trial Protocol, for the specific read times).
Each MIC was determined by comparing growth results in antibiotic wells with the growth patterns expressed in the 2 control wells (identified as the "Growth well" and the "Control well"). Initial data analysis was performed by comparing the initial Test MIC results with the initial Reference MIC results. As indicated in the Clinical Trial protocol, isolates that exhibited a ≥ 2 dilution error (discrepancy) between the Test and the Reference panel were repeated in triplicate. Final data analysis was performed by comparing the initial Test results to the repeat Reference results. Discrepancies were considered resolved when the repeat Reference result was in Essential Agreement with the initial Test result. An additional data analysis was also performed using repeat results from both the Reference and the Test panels. The Initial, Final, and Additional Data Analyses summaries are presented separately and are identified accordingly.
Both Clinical Trials consisted of 3 different test phases; Efficacy, CDC Challenge, and Reproducibility. Quality Control was performed daily. Data from the Efficacy and CDC Challenge phases were evaluated using the same Error and Agreement definitions.
*BASF, Parsippany, NJ,
4
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
MAY 1 0 1999
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Sharolyn J. Lentsch Regulatory Affairs Manager Dade Microscan, Inc. 1584 Enterprise Boulevard West Sacramento, CA 95691
Re: K983408
Trade Name: Dried Gram-Negative and Gram-Positive MIC/Combo Panels/Trovafloxacin Product Code: JWY Dated: March 31, 1999 Received: April 1, 1999
Dear Ms. Lentsch:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
5
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"
Sincerely yours,
Steven Sutman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
Dade MicroScan Inc. Dade MicroScan Dried Gram-Negative and Gram-Positive MIC/Combo Panels with Trovafloxacin Premarket Notification
Intended Use Statement
510(k) No .:
983408
Device Name:
Indications for Use:
MicroScan® Dried Gram-Negative and Gram-Positive MIC/Combo Panels with Trovafloxacin (0.03 - 8 mcg/ml on the gram-negative panels and 0.06 - 8mcg/ml on the gram-positive panels)
To determine gram-negative and gram-positive bacterial susceptibility against the antimicrobial agent Trovafloxacin.
Organisms with indications for testing* include:
Gram-Negative Bacteria Escherichia coli Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Gram-Positive Bacteria Methicillin susceptible Staphylococcus aureus Methicillin susceptible Staphylococcus epidermidis Enterococcus faecalis Streptococcus agalactiae (Gp.B) Streptococcus pyogenes (Gp.A)
- As taken from the Indications and Usage section of the manufacturer's package insert (Issued: December 1997).
The MicroScan® Dried Gram-Negative and Gram-Positive MIC/Combo Panels with Trovafloxacin are not intended for use with Streptococcus pneumoniae and viridans streptococci.
Woody Dubois
510(k) Number
Prescription Use (Per 21 CFR 801.109)
OR
Over-The Counter Use
(Optional Format 1-2-96)